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The Role of Osteocytes in Temporomandibular Joint Diseases 
Abstract 
Marianne Demirdji 
Temporomandibular joint disorders (TMJDs) are a highly prevalent spectrum of conditions occurring in 
about 6 to 12% of the adult US population totaling over 10 million people and costing billions of dollars 
in health care and lost productivity. TMJDs frequently present with pain, functional limitations and joint 
sounds associated with degenerative joint disease, an osteoarthritis (OA)-like condition that significantly 
affects the quality of life due to its impact on critical functions such as eating and speech. While the 
etiologies of the temporomandibular joint (TMJ) OA remain unknown, due to the propensity of these 
disorders in adolescent females- an age group that coincides with orthodontic treatment- orthodontic 
therapy has often been attributed as a causative or predisposing factor for TMJ OA. Furthermore, severe 
forms of these disorders such as idiopathic condylar resorption impact on the orthodontist’s ability to 
deliver predictable treatment outcomes. Thus, understanding the causation or predisposing factors for 
TMJ OA are of critical importance to our profession.  
The loss of cartilage extracellular matrix and a compromised subchondral bone are characteristic features 
of OA of the TMJ. While previous concepts of OA pathogenesis have proposed that cartilage loss is a 
primary contributor or initiator of OA, more recently it has become clear that cartilage-bone cross-talk are 
key elements in the pathogenesis of OA. Thus, altered bone quality including its increased or decreased 
density are known to lead to cartilaginous defects and progression of OA. Bone quality in turn is 
determined by bone forming and degrading cells including osteoblasts, osteocytes and osteoclasts. 
Although osteocytes have come to be recognized as key regulators of bone quality, their role in 
contributing to OA is not currently known. Published data has shown that osteocyte-mediated remodeling 
is essential for bone and joint health in long bones. More specifically, we have shown that mice with 
osteocyte specific ablation of matrix metalloproteinase-13 (MMP13), which is involved in perilacunar 
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remodeling (PLR) by osteocytes have bone quality defects due to collagen disorganization and matrix 
hypermineralization. However, the role of osteocyte function and osteocyte-mediated bone remodeling in 
TMJ OA remains unknown. Because OA is a disorder that involves complex and as yet largely unknown 
cross-talk between cartilage and subchondral bone, we anticipate a potential link between altered bone 
metabolism through loss of MMP-13 in osteocytes and TMJ OA. Our long-term goal is to understand the 
contribution of osteocyte-mediated bone phenotypic changes to the progression and severity of TMJ OA 
by testing the hypothesis that altered PLR through osteocyte-specific knockdown of MMP13 aggravates 
chemically-induced TMJ OA.  Towards this long-term goal, here we performed studies to address the 
following Specific Aims: 
1. Establish and confirm a reproducible and effective method for intra-articular injection of OA-
inducing agent, monosodium iodoacetate (MIA) by administration of Fast Green dye. 
2. Using data from previous studies on mouse knee joint and rat TMJ, test and establish an effective 
dose of an OA-inducing agent, monosodium iodoacetate (MIA) that results in OA-like changes in 
the mouse TMJ.   
3. Histologically quantify TMJ health via modified Mankin scoring in WT and MMP13OCY-/- male 
mice. 
Besides providing fundamental information on osteochondral interactions and the role of each of these 
tissues to the initiation and / or progression of TMJ OA, this study will be important in better 
understanding the pathogenesis of this disorder and in providing insights into potential therapeutic targets 
to prevent or alleviate degenerative diseases of the TMJ. Furthermore, determination of an effective MIA 
dose that generates TMJ OA will establish a mice model for TMJ OA that could be valuable for future 
studies to identify disease mechanisms.   
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CHAPTER 1: INTRODUCTION 
1.1. The TMJ in Health and Disease 
Temporomandibular Joint Disorders (TMJDs) are a highly prevalent spectrum of conditions occurring in 
about 6 to 12% of the adult US population totaling over 10 million people and costing billions of dollars 
in health care and lost productivity. Patients with TMJDs frequently present with facial pain and 
headaches, joint sounds and functional limitations that significantly affect the quality of life due to its 
impact on critical functions such as eating and speech. Approximately 10-25% of patients with 
temporomandibular joint (TMJ) pain demonstrate features of TMJ osteoarthritis (OA).1,2 TMJ OA is a 
condition that is classified as low-inflammatory arthritic condition, implying it’s chronic and slow onset.1 
Patients with TMJ OA often present with other crippling co-morbidities such as chronic pain and 
fibromyalgia, and have also been reported to have elevated levels of suicidal ideation, depression, and 
anxiety as compared to the general population.3,4 Therefore, new therapies to treat TMJD are clearly 
needed. While the etiologies of the TMJ OA remain unknown, due to the propensity of these disorders in 
adolescent females, an age group that coincides with orthodontic treatment, orthodontic therapy has often 
been attributed as a causative or predisposing factor for TMJ OA.1,5 Furthermore, severe forms of these 
disorders such as idiopathic condylar resorption impact on the orthodontist’s ability to deliver predictable 
treatment outcomes. Thus, understanding the causation or predisposing factors for TMJ OA are of critical 
importance to our profession. 
Joint health and optimal function in the TMJ as well as in the appendicular skeleton is a product of 
healthy articular cartilage, soft connective tissues including ligaments surrounding the joint, and 
subchondral bone. Defects in any of these can disrupt the crosstalk among these tissue that can lead to 
disease. Though there is evidence to show that this interaction between the various tissues in the joint are 
important in joint health and disease, the cellular and molecular mechanisms of this crosstalk are less 
clear. We have recently found that osteocytes in subchondral bone play a critical causal role in the 
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progression of joint disease. Specifically, we have found that osteocyte-mediated defects in subchondral 
bone contribute to the progression of OA of the knee joint (see Chapter 2). Given that the TMJ is a unique 
joint with distinct developmental origin, composition and function that are different from the knee and 
other appendicular joints, these findings may not be readily translatable to the TMJ.6 Therefore, we 
propose to determine the extent to which defects in osteocyte function contribute to the progression and 
severity of TMJ OA. 
1.2. Contribution of Matrix Metalloproteinases and Perilacunar Remodeling to Joint Degeneration and 
OA 
Matrix metalloproteinases (MMPs) are a family of 25 enzymes that are characterized by their 
extracellular matrix substrate specificity, zinc-dependent activity, extracellular inhibition by tissue 
inhibitors of metalloproteinases (TIMPs), secretion as a zymogen and sequence similarities.7 When 
MMPs are divided by functionality, MMP13 is identified specifically as a collagenase, with its primary 
substrates being helical collagens such as types I and II collagen, the predominant collagens found in 
bone and cartilage, respectively. Osteoblasts and chondrocytes express MMP13 and are directly involved 
with the degradation of collagen I and II.2 Indeed, MMP13 expressed by chondrocytes is a key proteinase 
implicated in cartilage matrix degradation and propagation of OA.6 In contrast to the known contributions 
of MMP13 to cartilage matrix loss, the effects of altered levels MMP13 expressed by bone cells 
particularly osteocytes to OA remains largely unknown. This information is of critical importance due to 
the fact that altered subchondral bone phenotype is increasingly implicated in contributing to the 
pathogenesis of OA. Specifically, it has been shown that increased or decreased subchondral bone density 
leads to secondary adverse changes in overlying cartilage and the perpetuation of OA.8–10 As bone cells 
are overloaded in OA, there are extensive changes to the structural framework of the subchondral bone. 
Some visible features include but are not limited to cartilage thickening, sclerosis, osteophytes, and bone 
marrow lesions. As the OA progresses, the cartilage layer thickens and becomes increasingly calcified, 
effectively reducing its primary function of diffusing loads. From these studies, it has been concluded that 
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the subchondral bone and overlying cartilage effectively function together to promote distribution of 
mechanical loads. Thus, not only do perturbations in cartilage health induce or aggravate bone 
degenerative changes, but primary or secondary changes in bone or poor bone quality perpetuate cartilage 
degeneration.8,9,11 This interplay between cartilage and bone make the understanding of the effect of one 
tissue on the other extremely critical to understanding and preventing OA. 
In this context, our studies show that the MMP13 ablation results in defective bone matrix organization 
and impaired bone quality in long bones, defects that we trace to impaired osteocyte function. Similarly, 
the administration of glucocorticoid represses MMP13 expression in osteocytes in long bones and in the 
mandible in proximity to defects in bone matrix collagen and mineral organization in the perilacunar 
regions.3,12 These lacunae house osteocytes and have a spanning network of canaliculi that have a variety 
of proposed functions including perilacunar remodeling (PLR).3 PLR is a process where osteocytes 
housed in lacunae resorb and replace the local bone matrix to achieve stable systemic mineral levels. The 
canaliculi off-shooting from the lacunae depend on this remodeling to maintain connectivity of osteocytes 
to one another and to the vascular supply. In the absence of PLR, there is observed degeneration of the 
osteocyte lacuno-canalicular network, collagen disorganization, and matrix hypermineralization. Our 
preliminary analysis of bone from mice with osteocyte-specific MMP13 ablation indicate that cell-
intrinsic MMP13 is required for normal PLR and bone homeostasis in long bones (see Chapter 2). 
However, the consequences and contributions of the resulting changes in bone phenotype to fibrocartilage 
health and TMJ OA has not been elucidated. Our proposed studies will set the foundation to elucidate the 
contributions of subchondral osteocytes and bone quality to cartilage degeneration and OA progression in 
the TMJ. 
1.3. Murine Mandibular Anatomy 
The mandible develops by intramembranous ossification with the earlier developing Meckel’s cartilage 
serving as a template. Nevertheless the condyle develops endochondrally as a secondary cartilage.13 This 
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is of significance because this secondary cartilage of the condyle serves as a growth site for the mandible, 
whereby chondrocytes proliferate to promote growth. Besides functioning as a growth plate, the condylar 
cartilage has an articular role that includes responding to functional and masticatory stresses. Following 
growth, the cartilage remains to continue serving as articular surface for the joint.14 Additionally, the 
shape and location of the TMJ changes in murine and human models with age.15  Liang et al., 
characterized the development of the murine TMJ from embryonic day 13.5 to post-natal day 180.16 They 
characterize TMJ formation over three stages: initiation, growth, and cavitation. The condyle develops 
upwards into the glenoid fossa with which it articulates. Furthermore, through proliferation and apoptosis 
that is regulated by a variety of transcription factors and MMPs, the murine condyle develops into the 
skeletally mature state at the 3-month mark of the animal’s life.16 The posterior portion of the condyle 
displaces posteriorly – lending to the up and back position of the condyle.17  
1.4. Methods to induce TMJ OA – particularly Monosodium Iodoacetate (MIA) 
MIA has been utilized for osteoarthritis induction for over 20 years, with its effects on joints 
characterized extensively. Localized injection of MIA into the synovial space of joints in the appendicular 
skeleton as well as in the rat TMJ results in a cascade of events affecting the function of chondrocytes. 
The metabolism of chondrocytes is impaired resulting in subsequent cartilage degeneration. Histological 
analysis has demonstrated this destruction is comparable to that of human OA.18  While previous studies 
have used MIA in mediating mice knee joint OA and rat TMJ OA, no information is currently available 
currently in the dosing and effects of MIA in the mouse TMJ.2,19–22 We will use the dosing and outcomes 
data from these studies to test the calculated MIA dose bracket and temporal effects in inducing OA in the 
mouse TMJ.  Current mouse TMJ OA models include dietary models, forced mouth opening, occlusal 
adjustments, and chemical induction. Dietary models are frequently used and present a non-invasive 
approach to discerning how changes in mechanical loading alter tissue phenotype. However, varying the 
pellet hardness (normal diet being hard pellets; experimental being soft) or size is often found to be 
insufficient in producing degenerative changes in the TMJ.13 Additionally, the joint changes in this model 
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are not thoroughly characterized. Forced mouth opening models present an aggressive model to induce 
TMJ changes which have notable outcomes such as subchondral bone thickening, increased expression of 
specific genetic markers, and chondrocyte irregularities.23 However, custom designed springs on mice 
present logistical issues to maintain the spring, and variations in reproducibility of loading forces. 
Malocclusion models for TMJ OA such as placement of a unilateral bonded wire to irregularly load the 
TMJ are not well characterized.24 Studies using chemical approaches to induction of TMJ OA show 
reproducible findings, are well-characterized and present a reliable option for TMJ induction.25 Current 
approaches include use of complete Freund’s adjuvant and MIA. Freund’s adjuvant-induced arthritis is 
highly inflammatory with features similar to that of rheumatoid rather than osteoarthritis.26 In contrast, the 
MIA OA model has been used to successfully and reliably induce OA-like disease in rat and rabbit and in 
the rat TMJ.2,19–22  
1.5. Summary and Significance 
A review of the literature and previously adopted methods led us to use MIA for inducing OA in the 
mouse TMJ. This required modifying approaches, doses and timelines that have previously been 
characterized in the mouse knee joint and rat TMJ to establish both the optimal conditions and to 
effectively administer MIA into the mouse TMJ to result in reproducible TMJ OA. Given the voids in our 
knowledge on the role of osteocyte-mediated bone remodeling in TMJ OA and because OA is a disorder 
that involves complex and as yet largely unknown cross-talk between cartilage and subchondral bone, we 
propose to explore the potential link between altered bone metabolism through loss of MMP13 in 
osteocytes and TMJ OA. Our overall goal is to understand the contribution of osteocyte-related bone 
phenotypic changes to the progression and severity of TMJ OA. Because the etiopathogenesis of TMJ OA 
is poorly understood, current treatments are largely palliative and designed to alleviate symptoms rather 
than rational and specific approaches to address cause(s) of these disorders. With increasing severity of 
the disease, it is treated with a spectrum of progressively invasive measures - from observation to full 
joint replacement. The proposed studies will not only provide fundamental information on osteo-chondral 
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interactions and the role of each of these tissues to the initiation and / or progression of TMJ OA, but will 
be important in better understanding the pathogenesis of this disorder and in providing insights into 
potential therapeutic targets to specifically prevent or alleviate degenerative diseases of the TMJ. For 
example, if the effect of bone phenotype on fibrocartilage degeneration is demonstrated, then optimal 
treatment strategies for OA might include targeting both the bone and cartilage compartments. Also, by 
focusing on the TMJ rather than the hyaline cartilage joints, we will be able to decipher the specifics of 
fibrocartilage responses to altered bone quality, that will be critical to understanding disease progression 
that is unique to the TMJ. Thus, the findings will be highly relevant to potential therapies that are specific 
for TMJ OA. 
Previous studies have shown that systemic and osteocyte-specific ablation of MMP13 interferes 
with PLR in the mouse femur and tibia resulting in altered collagen matrix organization and 
hypermineralization in the trabecular compartment of long bones.6 These defects manifest as bone 
sclerosis and canalicular network degeneration in subchondral bone and exacerbate the severity of joint 
degeneration in appendicular joints. Specifically, defective PLR results in full-thickness cartilage loss and 
severe bone sclerosis in the knee joint of MLI mouse model of OA as compared to moderate articular 
cartilage degeneration in MLI WT mice (see Chapter 2). Though our preliminary data support a causal 
role for osteocytic PLR in appendicular joint disease, the extent to which proteinases involved PLR such 
as MMP13 play a causal role in TMJ OA remains to be determined. Equally importantly, while we show 
the adverse effect PLR defects in subchondral bone on hyaline cartilage joint, it is not yet clear how these 
boney changes impact the progression of TMJ OA. Therefore, to evaluate the causal role of PLR in TMJ 
OA, we performed initial studies to evaluate the TMJ OA phenotype in MMP13OCY-/-  mice in the MIA 
model using the optimal dose conditions. 
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CHAPTER 2: PREVIOUSLY PUBLISHED MATERIALS 
 
2.1. PLR is Controlled by Regulating Essential PLR Enzymes 
Osteocyte specific MMP13 null mice that will be used in these studies have been used to generate 
important preliminary data that points to the potential role of PLR in TMJ OA. The importance of 
osteocyte-mediated PLR in health and disease has been characterized by studying the effects of enzymes 
that regulate bone remodeling on this process. Several osteocyte derived proteins have been implicated in 
PLR including cathepsin K, MMP13, MMP14, MMP2, TRAP, carbonic anhydrase 2, and the Na/H+ 
exchanger.12 Deficiency in each of these key enzymes impairs canalicular networks and yields other 
hallmarks of defective PLR. More specifically, dysregulation of bone remodeling caused by systemic or 
osteocyte-specific ablation of MMP13 significantly compromises bone quality (Figure. 2.1). This 
includes aberrant collagen organization, hypermineralization and decreased resistance to fracture.12 
Figure 2.1. MMP-13-deficiency results in increased trabecular bone volume and the altered distribution 
cortical bone mineralizationThe trabecular bone contoured from the proximal region of the tibia 
confirms previous observations that MMP13−/− bones have significantly increased trabecular bone volume 
fraction (BV/TV; p < 0.05) (A, B, E, F). MMP13-deficiency did not affect the geometric structure of the 
cortical bone (cortical thickness; p = 0.52) (C, D, G). Nonetheless, a histographic plot of the cortical bone 
Figure 1. MMP-13-deficiency results in increased trabecular bone volume and the altered
distribution cortic l bone mineralization
The trabecular b ne cont ured from the pr ximal region of the tibia confirms previ us
observations that MMP-13−/− bones have significantly increased trabecular bone volume
fraction (BV/TV; p < 0.05) (A, B, E, F). MMP-13-deficiency did not affect the geometric
structure of the cortical bone (cortical thickness; p = 0.52) (C, D, G). Nonetheless, a
histographic plot of the cortical bone tissue mineral densities (Cortical TMD) reveals that
MMP-13−/− mice have significantly altered TMD distribution (p < 0.001), characterized by
an increased incidence of lower and higher TMD compared to the WT (H). This can in part
be explained by the osteoid remnants, which stain red with Safranin-O, that are
predominantly observed in the middle and proximal aspects of the tibia (I). However there
were no detectable differences in Safranin-O staining in the distal region near the
tibiofibular junction where bulk of the subsequent analyses were performed (J).
Tang et al. Page 16
J Bone Miner Res. Author manuscript; available in PMC 2013 September 01.
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tissue mineral densities (Cortical TMD) reveals that MMP13 OCY-/- mice have significantly altered TMD 
distribution (p < 0.001), characterized by an increased incidence of lower and higher TMD compared to 
the WT (H). This can in part be explained by the osteoid remnants, which stain red with Safranin-O, that 
are predominantly observed in the middle and proximal aspects of the tibia (I). However there were no 
detectable differences in Safranin-O staining in the distal region near the tibiofibular junction where bulk 
of the subsequent analyses were performed (J). 
2.2. PLR is suppressed in human joint disease 
Although the abnormal subchondral bone of post-traumatic OA (PTOA) and osteonecrotic joints has been 
well-described, the integrity of PLR in these conditions has not previously been known.27–29 We found 
that subchondral bone from patients with PTOA and osteonecrosis exhibits each of the classical hallmarks 
of defective PLR. Femoral head subchondral bone from patients with glucocorticoid- induced 
osteonecrosis has reduced levels of MMP13, disorganized collagen, truncated canaliculi, smaller lacunae, 
and hypermineralization (Figure 2.2). Our preliminary data indicate that the same hallmarks are present in 
PTOA tibial plateaus from veterans receiving knee replacements.3 Among these, the most compelling 
evidence of PLR suppression is that canalicular length is reduced by 56% in PTOA bone, relative to bone 
from non-PTOA cadaveric donors (Figure 2.3, p=0.003). Furthermore, canaliculi on the medial side of the 
tibial plateau, the most common site of PTOA, appear to be shorter than those on the relatively healthier 
lateral side of the same joint. Collectively, our findings strongly support the conclusion that PLR is 
suppressed in human osteonecrosis and in PTOA. However, analysis of tissues with terminal disease does 
not clarify whether PLR suppression contributes to disease progression, or is a result of the disease 
process. Thus, there is substantial value to performing in vivo mechanistic studies to understand the 
temporal relationship between PLR and OA and the direct contributions that aberrant PLR makes to OA. 
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Figure 2.2. PLR suppression in human osteonecrosis. Trabeculae from the sclerotic regions of human 
femoral heads (B,E,H,K,N) show hallmarks of defective PLR relative to those distant from the lesion 
(A,D,G,J,M). These include reduced MMP13 expression (IHC, A–C) (scale bar, 20 µm), defects in 
collagen organization (picrosirius red stain, D–F) (scale bar, 50 µm), and reduced canalicular length 
(silver nitrate stain, G–I). Bar graph represents mean ± SEM of n ≥ 3 regions from human cadaveric or 
human osteonecrotic bone samples, * p-value ≤ 0.05 compared to control. Xray tomographic microscopy 
shows hypermineralization (L, red arrows) and reduced lacunar size (O) in osteonecrotic bone (K,N) 
relative to trabeculae that are more distant (J,M). Vertical lines (L,O) signify peak volumes.  
www.nature.com/scientificreports/
8Scientific RepoRts | 7:44618 | DOI: 10.1038/srep44618
Figure 7. Organization and composition of human osteonecrosis subchondral bone has hallmarks of 
defective perilacunar remodeling. Trabeculae from the sclerotic regions of human osteonecrotic f moral 
heads (B,E,H,K,N) show histologic and radiographic hallmarks of defective perilacunar remodeling relative to 
trabeculae that are distant from the lesion (A,D,G,J,M). These include reduced MMP-13 expression as assessed 
by immunohistochemistry for MMP-13 or negative control (A–C) (scale bar = 20 µm), defects in collagen 
organization as assessed using picrosirius red staining (D–F) (scale bar = 50 µm), and reduced canalicular 
length as assessed by silver nitrate staining (G–I). For graph, bars represent me n ± SEM of n ≥ 3 regions from 
either normal human cadaveric or human osteonecrotic bone samples, * p-value ≤ 0.05 compared to control. 
As in GC-treated mouse bone, SRµ T shows hypermineralization (L) (red arrows highlight hypermineralized, 
sclerotic, collagen layers) and reduced lacunar size (O) in the bone from human osteonecrosis lesions (K,N) 
relative to trabeculae that are more distant (J,M). Vertical dotted lines signify peak lacunar volume values.
Figure 8. Schematic model comparing balanced perilacunar remodeling with glucocorticoid-mediated 
suppression. Within the bone matrix during normal perilacunar remodeling (A), there exists extensive 
lacunocanalicular connectivity, linearized collagen, and maintenance of mineral content around the osteocyte 
lacuna. Inset shows linearized collagen. In the presence of excess glucocorticoids (B), perilacunar remodeling 
is suppressed. Dysregulation of osteocyte enzyme expression likely precedes changes in bone matrix collagen 
alignment, lacunocanalicular circulation, and mineralization status; all of which contribute to the poor bone 
quality, sclerosis and increased fracture risk observed in osteonecrosis. Inset shows disorganized collagen 
matrix with accompanying hypermineralization. Illustration by M. Ouchida.
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Figure 2.3. Disrupted lacunocanalicular networks in human OA subchondral bone. Control cadaveric (A, 
C, D) and OA (B, E, F) specimens stained with Safranin-O/ Fast Green and imaged at 0.5x (A, B) or 10x 
(C-F) magnification displayed differences in articular cartilage and subchondral bone morphology on the 
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lateral and medial sides of the tibial plateau. Subsequent analyses compared the indicated regions of 
interest (black boxes in A, B) between control and OA specimens, and between the less affected lateral 
side with the more severely degraded medial side. These identified regions of interest in Ploton silver 
stained sections were evaluated at low (4x, G-J) and high (100x, K-N) magnification to visualize the 
lacunocanalicular network of subchondral bone. Quantification of lacunocanalicular area normalized to 
bone area (O) and canalicular length (P) revealed significant OA-dependent reductions in both parameters 
(n=5). Scale bars are 400 µm in C-F, 200 µm in G-J, and 20 µm in K-N. *p<0.05 compared to respective 
regions of control specimens, p<0.05 between regions by Holm-Sidak post-hoc tests.  
 2.3. PLR suppression compromises subchondral bone quality and plays a causal role in PTOA 
In addition to our findings on effects of dysregulated PLR on trabecular bone in long bones, we have 
found sclerotic bone and abrogated canalicular networks (Figure 2.4) in subchondral bone in mice with 
either systemically ablated MMP13, or with osteocyte-specific knockout of MMP13.12 Our preliminary 
data further support the causal role of PLR suppression in joint disease. Using an established medial 
collateral ligament (MLI) injury model of knee joint PTOA in which the medial collateral ligament is 
transected and the medial meniscus is removed, we tested the hypothesis that PLR suppression would 
exacerbate the severity of PTOA.30,31 While the analyses are still underway, the preliminary data support 
this hypothesis. Relative to the anticipated moderate degeneration of articular cartilage in MLI wild-type 
mice Figure 2.5B, the degeneration in an osteocyte-intrinsic model of PLR suppression (TBRII OCY-/-) 
demonstrated full-thickness cartilage loss and severe bone sclerosis as visualized histologically (Figure 
2.5D). These findings support and extend the conclusions derived from the osteonecrosis model, in which 
glucocorticoid excess affected multiple cell populations. Specifically, we find that osteocyte-intrinsic 
suppression of PLR is sufficient to exacerbate the severity of joint degeneration. The extent to which 
similar processes participate in the degeneration of the TMJ remain to be determined and are the focus of 
this study. 
	 12	
 
Figure 2.4. Osteocyte-intrinsic ablation of the PLR enzyme MMP13 causes subchondral bone sclerosis 
and canalicular network degeneration. Osteocyte-specific ablation of MMP13 results in trabecular bone 
sclerosis (A,B) and reduced canalicular length (silver nitrate stain, C,D). These findings complement 
those in human PTOA and in systemic MMP13-deficient mice, which also show poor bone quality with 
significantly reduced work- to-fracture (E). * p-value ≤ 0.05 compared to control. 
 
Figure 2.5. Increased PTOA severity in TβRIIOCY-/- mice shows critical role of osteocytes in joint 
disease. Meniscal/ligamentous injury (MLI) in WT mice results in a PTOA phenotype with loss of 
proteoglycan staining and subchondral bone sclerosis (Safranin- O/Fast Green stain, B) compared with 
non- injured controls (A) (scale bar = 20 µm). Defective PLR, induced by osteocyte-specific ablation of 
TβRII, exacerbates cartilage degeneration and subchondral bone sclerosis in the presence of injury (D) 
compared with uninjured TβRII OCY-/-. Canalicular networks are disrupted in TβRII OCY-/- mice (G, H) 
compared with WT mice (E,F). Blinded reviewers consistently ranked the joints of the MLI TβRII OCY-/- 
mice as the most severe PTOA phenotype. This qualitative preliminary data is representative of N=5 
mice/group. 
30 
analysis of tissues with terminal disease does not clarify 
whether PLR suppression contributes to disease 
progression, or is a result of the disease process. Thus, 
there is substantial value to performing in vivo 
mechanistic studies to understand the temporal 
relationship between PLR and OA and the direct 
contributions that aberrant PLR makes to OA.  
2.3 PLR suppression compromises subchondral bone quality and plays a causal role in PTOA 
In addition to our findings on effects of dysregulated PLR on trabecular bone in long bones, we have 
found sclerotic bone and abrogated canalicular networks (Fig. 4) (Tang et al., 2012) in subchondral 
bone in mice with either systemically ablated MMP13, or with osteocyte-specific knockout of MMP13. 
Our preliminary data further support the causal role of PLR suppression in joint disease. Using an 
established medial collateral ligament (MLI) injury model of knee joint PTOA in which the medial 
collateral ligament is transected and the medial meniscus is removed (Kamekura et al., 2005; 
Sampson et al., 2011), we tested the hypothesis that PLR suppression would exacerbate the severity 
of PTOA. While the analyses are still underway, the preliminary data support this hypothesis.  
Relative to the anticipated moderate degeneration of articular cartilage in MLI wild-type mice (Fig. 
5B), the degeneration in an osteocyte-intrinsic model of PLR suppression (TERIIOCY-/-) demonstrated 
full-thickness cartilage loss and severe bone sclerosis as visualized histologically (Fig. 5D).  These 
findings support and extend the conclusions derived from the osteonecrosis 
model, in which glucocorticoid excess affected multiple cell populations. 
Specifically, we find that osteocyte-intrinsic suppression of PLR is sufficient 
to exacerbate the severity of joint degeneration.  The extent to which similar 
processes participate in the degeneration of the TMJ remain to be 
determined and are the focus of this study.  
Figure 4. Osteocyte-
intrinsic ablation of the 
PLR enzyme MMP13 
causes subchondral bone 
sclerosis and canalicular 
network degeneration. 
Osteocyte-specific ablation 
of MMP13 results in 
trabecular bone sclerosis 
(A,B) and reduced 
canalicular length (silver 
nitrate stain, C,D). These 
findings complement those 
in human PTOA and in 
systemic MMP13-deficient 
mice, which also show poor 
bone quality with 
significantly reduced work-
to-fracture (E). * p-value ≤ 
0.05 compared to control.   
20μm
20μm
0
0.1
0.2
0.3
0.4
Tr
ab
ec
ul
ar
 B
V
/T
V *
WT
MMP13OCY‐/‐
0
2
4
6
8
C
an
al
ic
u
la
r 
Le
ng
th
 (μ
m
)
*
WT
MMP13OCY‐/‐
0
5
10
15
20
25
30
Po
st
yi
el
d
 W
o
rk
‐t
o‐
fr
ac
tu
re
 [N
*m
m
]
*
WT
MMP13‐/‐
W
T
M
M
P1
3O
CY
‐/
‐
M
M
P1
3O
CY
‐/
‐
W
T
A B C D E
Figure 3. PLR disruption in subchondral bone of veterans correlates with 
the severity of PTOA. PTOA tibial plateau samples demonstrate a loss of 
cartilage thickness, reduced proteoglycan staining in the superficial zone, 
and cartilage fibrillation (Safranin-O/Fast Green stain, D,E) compared to 
healthy cadaveric controls (A,B). Canalicular network organization is 
disrupted in the subchondral bone of PTOA tibial plateaus (silver nitrate 
stain, F), relative to healthy cadaveric tibial plateaus (C), and results in a 
reduction of canalicular length by 56.2% in arthritic samples compared to 
healthy samples (G). Bar graph represents mean ± SEM of n ≥ 3 regions in 
human subchondral bone from PTOA or healthy donors, * p-value ≤ 0.05 
compared to control. Samples from veterans receiving knee replacements 
due to severe PTOA were matched to healthy, non-PTOA cadaveric controls 
in age, sex, and BMI (H). 
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2.4 Experiments to Induce TMJ OA and Assay TMJ D generation 
Dr. Kapila has extensive experience in TMJ pathobiology for which he has been funded over the 
yea s by the NIH nd the AAOF. His r search group devel ped and characterized the first 
reproducible animal model of inflammatory TMJ disease (Kapila et al., 1995a) and were also the first 
to document the mandibulofacial growth changes in juvenile rheumatoid arthritis (JRA)-like disease 
of th  TMJ in this animal model (Tavakkoli et l., 1999). His laboratory was the first to characterize 
the MMPs expressed by TMJ cells (Kapila et al., 1995b), which has provided the foundation of 
subsequent work by several investigators in deciphering the TMJ disease progression and markers 
of disease. The preliminary data provided below demonstrates the technical and intellectual 
knowhow to conduct the studies proposed in 
this application, which include histochemical 
and biochemical assays on changes in 
cartilage matrix macromolecules (Fig. 6) and 
PCT analyses of subchondral bone porosity 
(Fig. 7). 
3. EXPERIMENTAL DESIGN AND METHODS
3.1 Aim 1: Establish and Characterize an MIA-Induced TMJ OA Model in Mice  
We will adapt a previously established monosodium iodoacetate (MIA)-induced mice knee OA model 
to the TMJ by determining the MIA dose and temporal effects on the initiation and progression of 
mouse TMJ OA assessed histologically and by PCT analyses.  
Figure 5. Increased PTOA severity in 
TβRIIOCY-/- mice shows critical role of OCY in 
joint disease. Meniscal/ligamentous injury 
(MLI) in WT mice results in a PTOA
phenotype with loss of proteoglycan staining
and subchondral bone sclerosis (Safranin-
O/Fast Green stain, B) compared with non-
injured controls (A) (scale bar = 20 μm).
Defective PLR, induced by osteocyte-specific
ablation of TβRII, exacerbates cartilage
degeneration and subchondral bone sclerosis in
the presence of injury (D) compared with
uninjured TβRIIocy-/-. Canalicular networks are
disrupted in TβRIIocy-/- mice (G, H) compared
with WT mice (E,F).  Blinded reviewers
consistently ranked the joints of the MLI
TβRIIocy-/- mice as the most severe PTOA
phenotype. This qualitative preliminary data is
representative of N=5 mice/group.
TβRII OCY‐/‐ + MLIWT + MLIWT TβRII OCY‐/‐
20 μm 20 μm 20 μm 20 μm
20 μm 20 μm 20 μm 20 μm
A B C D
E F G H
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2.4 Experiments to Induce TMJ OA and Assay TMJ Degeneration 
Our lab (Kapila et al., 1995) has previously developed and characterized the first reproducible animal 
model of inflammatory TMJ disease and were also the first to document the mandibulofacial growth 
changes in juvenile rheumatoid arthritis (JRA)-like disease of the TMJ in this animal model.26 We have 
also characterized the MMPs expressed by TMJ cells, which provided the foundation of subsequent work 
by several investigators in deciphering the TMJ disease progression and markers of disease.32 The 
preliminary data provided below demonstrates the technical and intellectual know-how to conduct the 
studies proposed in this application, which include histochemical and biochemical assays on changes in 
cartilage matrix macromolecules (Figure. 2.6) and µCT analyses of subchondral bone porosity (Figure 
2.7). 
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Figure 2.6. In Vivo Effects of Estrogen (Est) on Collagen and Glycosaminoglycan (GAG) content of TMJ 
Fibrocartilage. Ovariectomized (OVX) young female mice were administered PBS or estrogen for seven 
days and TMJ or fibrocartilage harvested for histochemical staining (A and C) or biochemical assays for 
collagen (B) or GAG (D), respectively. (A) Masson’s trichome staining showing diminished collagen 
staining (blue) in TMJ fibrocartilage from estrogen treated mice relative to controls, that corresponds with 
loss of collagen as determined by hydroxyproline assay (B). (C) Safranin-O staining demonstrates 
decreased staining for GAG (orange) in TMJ fibrocartilage from estrogen treated mice relative to PBS 
control mice, which is confirmed quantitatively by Alcian Blue assay (D). Sham-operated mice were used 
as controls (P < 0.05). 
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Figure 2.7. In Vivo Effects of Estrogen (Est) on Subchondral Bone Porosity. Ovariectomized (OVX) 
young female mice were administered PBS or estrogen and TMJs retrieved for microCT after 28 days. 
Three-dimensional reconstruction (A) and coronal sections (B) of representative condyles show increased 
subchondral porosity. (C) This finding was confirmed quantitatively by analyzing the porosity in the 
subchondral zone (demarcated by the red line in the panel) and found to be statistically significant in mice 
administered estrogen relative to sham and PBS control mice (**P < 0.01).   
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CHAPTER 3: EXPERIMENTAL DESIGN AND METHODS 
3.1. Selected Mice and Allocated Groups 
A power analyses (see Statistical Analyses) indicates that a sample size of 4 specimens per group will 
result in a statistical significance at the 0.05 level (two-tailed). Statistical analyses on the effects of MIA 
on OA severity and other quantitative data will be performed as described below (see Statistical 
Analyses). Mice were generated by breeding homozygous MMP13-floxed mice that possess loxP sites 
flanking exons 3, 4, and 5, which encode the enzyme’s active site with hemizygous -10kb-DMP1-cre+/- 
mice, which express Cre recombinase primarily in osteocytes.33,34 Half of the mice from the resulting 
cross were DMP1-Cre+/-; MMP13flfl (named MMP13 OCY-/-) and half were DMP1-cre-/-; MMP13fl/fl 
littermate controls (named WT mice), as confirmed by PCR genotyping. All experiments were initiated 
on 12-week old mice using animal procedures approved by the Institutional Animal Care and Use 
Committee of the University of California San Francisco and the Indiana University School of Medicine. 
Once determined, the final injection protocol was practiced until sufficient competence was achieved for 
establishment of the injection protocol as proposed in Aim 1. Mice used for dose determination in Aim 2 
was allocated as follows: four mice for the 0.10 mg (4 mg/kg) MIA dose, two for the 0.05 mg (2 mg/kg) 
MIA dose, and 3 for the saline group due to time constraints and limitations in animal availability. While 
this is insufficient to draw conclusions due to a lower power and sample size, conclusions can be drawn 
from the preliminary analysis to allow for further studies. In order to compare 28 day male WT vs 
MMP13OCY-/- as described in Aim 3, five samples were obtained per group. Representative male and 
female samples at 7 and 28 day WT and MMP13 OCY-/- were also collected for future studies and are 
displayed in Figures 9-11.  
3.2 TMJ Injection Protocol 
In order to establish a proper injection protocol, a variety of needle gauges, lengths, and paths of injection 
were attempted. A 30 gauge needle was determined to not effectively pierce the mouse tissue. From this a 
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25 gauge needle was used to effectively pierce through the mouse tissue. Differing lengths of needles 
were used and eventually decided based of efficacy of delivery. The influencing factors for this decision 
were the length of the mouse from the TMJ to the nose tip as well as the volume of the fluid to be injected 
to the TMJ. A 25 gauge 0.625 inch was eventually used for all injections. Differing angulations of 
injection were also tried which are detailed in the Discussion. The final chosen injection method was to 
insert and place the needle parallel to and directly inferior to the zygomatic arch, as medial as possible. 
The needle lies directly parallel to the mouse head. The needle is then inserted until it hubs against nose 
of mouse and lateral to mouse molars as shown in Figures 3.1A and 3.1B. When the needle hubs, the tip 
is nearly flush with cochlea.  
 
Figure 3.1. Injection into the TMJ. Characterizing and verifying an optimal method for intra-articular 
TMJ injection in the mouse. Lateral (A) and anterior (B) views showing direction of needle insertion. (C) 
Dissected mouse head showing Fast Green staining of condylar head and TMJ fossa (arrow).  
3.3 Procedure for Aim 1 
12 week old mice allocated for Aim 1 were euthanized post-injection via lethal dose of CO2, followed by 
cervical dislocation. Intra-articular administration of Fast Green dye was confirmed by TMJ dissection as 
A 
B 
C 
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demonstrated in Figure 3.1C. These procedures were modified as needed and repeated until injections 
were noted to deposit the dye into the joint as desired for future injections. Once an optimal method was 
identified, these experiments were repeated in anaesthetized mice to confirm the adequacy of this 
technique  
3.4 Procedure for Aim 2 
The TMJ OA was induced by injection of MIA dissolved in 10 µl saline into both TMJs of 12-week old 
mice using a 25 gauge 0.625 inch needle under anesthesia without surgical assistance. In establishing and 
characterizing OA TMJ model in mice, we performed preliminary dose-response analysis of the effects 
MIA administered into mouse TMJs. Using dose data from previous studies on MIA-induced OA in 
mouse knee joint and rat TMJ adjusted by joint volume and weight, respectively, we calculated a low and 
high range of MIA dose and optimal volume to use in the mouse TMJ.20,21,25,35 These calculations 
indicated a low MIA dose of 0.05 mg (2 mg/kg) and high MIA dose of 0.10 mg (4 mg/kg) in saline 
should generate reproducible OA in the mouse TMJ. Similarly, these studies have demonstrated joint 
changes characteristic of OA within 3 to 21 days of intraarticular administration of MIA.20,21,25,35 Thus 
using a small sample of mice and 10 µl of PBS or low (0.05 mg) or high (0.10 mg) dose of MIA we 
histologically assayed mice at 28 days following administration of MIA or PBS.  Un-injected control 
animals did not receive anesthesia or analgesics. All animals were allowed unrestricted activity, food, and 
water. At 28 days post injection (dpi), animals were euthanized via lethal dose of CO2, followed by 
cervical dislocation and hemi-mandibles were harvested for histological and radiographic analyses. The 
left hemi-mandible were frozen for future µCT studies.  The right hemi-mandible was fixed overnight in 
4% paraformaldehyde, decalcified, sectioned, stained with Safranin-O/Fast Green stain and OA severity 
determined through modified Mankin scoring. 
3.5 Procedure for Aim 3 and representative samples 
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Since OA studies will be performed at 7 and 28 following injection of MIA in 12-week old mice, for this 
part of the study, we analyzed tissues from representative control mice 13 weeks (controls for 7 dpi mice) 
and 16 weeks (controls for 28 dpi mice) of age. Representative samples at these time points for male and 
female WT and MMP13 OCY-/- were collected. Of these five samples each from WT and MMP13OCY-/- 16-
week old male mice (controls for 28 dpi) were analyzed per group for the current studies while the rest 
were banked for ongoing studies.  Un-injected animals did not receive anesthesia or analgesics. All 
animals were allowed unrestricted activity, food, and water. Mice were euthanized via lethal dose of CO2, 
followed by cervical dislocation. 
3.6 Histology and OA Quantitation 
The hemi-mandibles were dissected and fixed in 10% neutral buffered formalin and then decalcified in 
10% EDTA until fully decalcified, followed by serial ethanol dehydration and paraffin embedding. 
Coronal sections (6 µm thick) were generated using a microtome (Leica Microsystems, Buffalo Grove, 
IL) for Safranin-O/Fast Green stain.  
Safranin-O with Fast Green protocol was adapted from University of Rochester (University of Rochester 
Center for Musculoskeletal Research. Safranin O/Fast Green stain for Cartilage. 
https://www.urmc.rochester.edu/musculoskeletal-research/core- services/histology/protocols.aspx. 
Published 2017. Accessed May 1, 2018). Briefly, paraffin sections were deparaffinized, rehydrated, and 
stained in Weigert’s Iron Hematoxylin for 5 minutes then washed in water and differentiated in 1% acid-
alcohol. Slides were then incubated in 0.02% Fast Green for 15 minutes, followed by staining with 1.0% 
Safranin-O for 20 minutes and subsequently dehydrated, cleared, and mounted. Images were captured 
using a Nikon Eclipse E800 bright-field microscope for OA quantitation.  
A minimum of three sections of each condyle taken as close as possible to the midcoronal location of the 
joint were used to quantitate OA using modified Mankin score that is scored from 0 (normal cartilage) to 
14 (aggressive cartilage destruction)  as shown in Table 3.1. 36,37 
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Table 3.1. Modified Mankin Score used to characterize osteoarthritis severity37
  
3.7. Statistical Analyses and Data Management 
Sample Size Calculations: Power analysis was performed using conservative assumptions and based upon 
data from prior studies by our group and others. This analysis indicates an 80% chance of reaching 
statistical significance at the 0.05 level (two-tailed) with a sample size of 4 specimens per group. q1 = 
0.500 [MMP13OCY-/- mice with TMJ OA]; q0 = 0.500 [DMP1 mice with TMJ OA]; Alpha = 0.05 (2-sided); 
Beta = 0.20 (80% power); E = 1.3 - 0.5 = 0.80; S = 0.4. Five WT and five MMP13 OCY-/- mice at 16 weeks 
old were analyzed to assess for differences in OA severity. Histologic analysis was performed using the 
modified Mankin OA score. The panels of images were scored by 3 independent blinded graders. Scores 
were summed and averaged. These scores were used for the descriptive and statistical purposes. Data was 
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analyzed using Excel software with an unpaired two sample and two tail t-test with the assumption that 
the data is normally distributed.  
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CHAPTER 4: RESULTS 
4.1 Selected Method of Intra-articular Injection 
Due to the size of the mouse TMJ we used a 25 gauge 0.625 inch needle for all injections. After several 
trials we identified the optimal method of injections. This involved placing the needle parallel to and 
directly inferior to the zygomatic arch, as medial as possible relative to the nasal midline. With the needle 
lying directly parallel to the mouse head in a sagittal direction, it is the inserted into the skin until it hubs 
against nose of mouse and lateral to mouse molars. The solution is deposited within the glenoid fossa of 
the articulating TMJ condylar head. 
4.2 Histological Observations in Un-injected Control Mice 
Figures 4.1-4.3 demonstrate representative samples of mice from groups of either WT or MMP13OCY-/-, 
male and female mice at 13 weeks old (7 dpi controls) or 16 weeks (28 dpi controls). Statistical analyses 
were not conducted on these animals since each group is presented with a representative sample of n = 1.  
The females on average appear to have a slightly smaller width of Safranin-O staining in comparison to 
the males. The females additionally show slightly greater amount of Safranin-O staining throughout the 
neck of the condyles as compared to the males. Males generally show greater cellular disorganization that 
the females. Additionally, although there are shape differences in the condyles across the panels, this can 
be attributed to differences in sectioning protocol. However, female 28 dpi demonstrates significant 
flattening and shape irregularities as well as thinness of Safranin-O staining region. 
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Figure 4.1. Coronal sections of male versus female WT and MMP13OCY-/- TMJ at 13 weeks (7 dpi 
controls) and 16 weeks (28 dpi controls) with Safranin-O/Fast-green stain at 10x (un-injected controls) 
 
Figure 4.2. Coronal sections of male versus female WT and MMP13OCY-/- TMJ at 13 weeks (7 dpi 
controls) and 16 weeks (28 dpi controls) with Safranin-O/Fast-green stain at 20x (un-injected controls) 
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Figure 4.3. Coronal sections of male versus female WT and MMP13OCY-/-  TMJ at 13 weeks (7 dpi 
controls) and 16 weeks (28 dpi controls) with Safranin-O/Fast-green stain at 40x (un-injected controls) 
 
4.3 Effects of MIA on Induction of OA in the TMJ  
Figures 4.4 to 4.6 demonstrate coronal sections of saline versus MIA injected TMJs in WT mice at 28 dpi 
three different magnifications. Each panel represents a different animal. The first panel for 0.10 mg MIA 
dose demonstrates significant loss of cellularity and staining (black arrow) just above the subchondral 
bone. Slight loss of cellularity is also observed in first panel for 0.05 mg MIA dose (yellow arrow). A 
differential gradient of staining is observed for all samples. There is less Safranin-O staining with MIA 
than saline which appears to be more substantial with 0.1mg MIA than 0.05mg MIA. This is similarly 
exhibited for cellularity. 
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Figure 4.4. Coronal sections of TMJs from control PBS MMP13OCY-/- vs 0.05 mg MIA WT and 0.10 mg 
MIA WT mice at 28 dpi (10x magnification) 
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Figure 4.5. Coronal sections of TMJs from control PBS MMP13OCY-/- vs 0.05 mg MIA WT and 0.10 mg 
MIA WT mice at 28 dpi (20x magnification).  
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Figure 4.6. Coronal sections of TMJs from control PBS MMP13OCY-/- vs 0.05 mg MIA WT and 0.10 mg 
MIA WT mice at 28 dpi (40x magnification). 
 
The sample was quantified by Mankin scoring, but due to the lack of power for this group, statistical 
analyses was not performed. The modified Mankin scoring demonstrated that MIA at 0.10 mg dose 
appeared to have higher scores in all categories apart from cartilage erosion scoring. MIA at 0.05 mg dose 
was second highest in scoring again in all categories apart from cartilage erosion scoring. Cartilage 
erosion scoring shows the most variable results in comparison to all other OA features. 
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Figure 4.7. Modified Mankin Scores of TMJs from PBS control MMP13OCY-/-- vs 0.05 mg MIA WT and 
0.10 mg MIA WT mice.  
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Figure 4.8. Modified Mankin Scores of TMJs from PBS control MMP13OCY-/-- vs 0.05 mg MIA WT and 
0.10 mg MIA WT mice.  
 
4.4. Histological Observations and Quantitation in WT and MMP13ocy-/- Mice 
Figures 4.9 and 4.10 demonstrate coronal sections of male WT and MMP13OCY-/- - TMJs at 16 weeks of 
age (28 dpi controls), that were analyzed via modified Mankin scoring (Figures 4.11 and 4.12). There are 
visible histological differences between the samples such as the cellular organization in the cartilage 
layer, the cartilage surface, and the stain intensities. Sample 4 in Figure 4.10 demonstrates superficial 
fibrillation (black arrow); but does not go so deep as to demonstrates separation of the calcified and 
uncalcified layers. 
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Figure 4.9. Coronal sections of TMJs from 16 week-old (28 dpi controls) WT vs MMP13OCY-/- male mice 
(10x magnification). 
Figure 4.10. Coronal sections of TMJs from 16 week-old (28 dpi controls) WT vs MMP13OCY-/- male 
mice (20x magnification). 
	 31	
  
Figure 4.11.  Modified Mankin Scores in each of the four histological categories in 16 week-old (28 dpi 
controls) WT vs MMP13OCY-/- mice. 
 
Figure 4.11 demonstrates the modified Mankin scores in each histological category to be slightly higher 
than that of the MMP13OCY-/-. However there was no statistically significant differences between the two 
groups (P<0.05, two tailed, tcrit = 2.7) for each of the individual histological categories, which translated to 
having to accept the null hypothesis. The total Modified Mankin score was also found not to be 
statistically significantly different between WT and MMP13OCY-/- mice (P<0.05, two tailed, tcrit = 2.4). 
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Figure 4.12. Total Modified Mankin Score comparison between 16 week-old (28 dpi controls) WT vs 
MMP13OCY-/- mice. 
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CHAPTER 5: DISCUSSION 
This study established the foundations for investigation the presentation of OA in WT and 
MMP13OCY-/- specific to the TMJ. It was postulated that the osteocyte specific MMP13 knockout would 
result in an increased qualitative expression of OA due to the disorganization the canaliculi projecting 
from the osteocytes.3 These canaliculi have been associated with maintenance of bone quality.12 The 
direct mechanism is not yet established; however, PLR by virtue of these canaliculi is necessary to 
achieve bone homeostasis. Because the disorganization of the bony and chondrocytic matrices exposes 
the structures to degradation which clinically presents in the TMJ degeneration or osteoarthritis, it is 
expected that these studies would provide important insights in the role of osteocytes and subchondral 
bone to TMJ OA initiation and progression. 
5.1 Injection and Anesthetic Methods 
The initial portion of this study was aimed at elucidating the most effective and reliable method 
for intraarticular injection in order to use a chemically-mediated injury model of OA in the mouse TMJ. 
Previous studies have injected rabbit, rat or pig TMJs; however, this is the first study to demonstrate 
consistent intraarticular injection into the mice TMJ.29–31 This goal presented a multitude of difficulties. 
Some included the small size of the animal, the inability to find an effective anesthetic dose, as well as the 
differing anatomy of different age groups of the mice.  
To ensure reproducible and predictable OA induction that requires intraarticular delivery of MIA 
into the TMJ, we utilized the administration of Fast Green dye into the putative location of TMJ as 
described previously.25 A series of trials with different approaches of accessing and depositing the dye 
were undertaken starting with mouse heads to live mice under ketamine/xylazine injectable anesthetic to 
optimize intra-articular injections of fast green dye.  Anesthetized mice were euthanized post-injection via 
lethal dose of CO2, followed by cervical dislocation. The goal of these trials was to determine optimal 
access, precise location and volume of agent to be delivered. Intra-articular administration of the dye was 
	 34	
confirmed by TMJ dissection as demonstrated in Figure 3.1C. This work serves as an important 
springboard for undertaking future studies to establish temporal dependent outcomes with MIA in using 
osteocyte-specific MMP13 null mice.  
Initial methods involved injection from an infero-superior aspect using the masseter and posterior 
border of the mouse mandible as an anterior limit. The difficulty in using the injection direction was 
determining the vertical depth and medial to lateral depth of the TMJ with which to insert the needle. Too 
deep a vertical depth resulted in piercing of the temporal bone into the and death of the animal. Too 
lateral of an injection resulted in ineffective injection of the dye into the joint. The dye in this scenario 
would seep into the adjacent fascial tissue and did not reach the desired TMJ capsule location. This 
method was slightly more effective in younger mice that we anticipated using because the condyle tends 
to be more upright, and if a sufficient medial depth was realized without encroaching on the brain tissue, 
successful injection was achieved. However, after confirming this method of injection, transitioning to 
older mice to be used in our study resulted in poor injection success. Upon further investigation of the 
mouse anatomy as well as general growth, it was concluded that the condyle grows in an up and back 
direction.38 That is, using the vertical injection method on the correct aged mice resulted in completely 
missing the condyle due to the now posteriorly displaced location of the condyle. Using a group of 
correctly aged mice, a new injection protocol was devised.  
An additional difficulty was ensuring adequate depth of anesthesia for the mice. Using an 
inhalant method of anesthesia necessitates having a nose cone placed over the animal’s nasal portion to 
deliver the gas. However, this impeded the eventual selected method of injection as described in the 
Methods section. Furthermore, due to variabilities in gender and genetic line, the mice required different 
doses of anesthetic to achieve proper anesthetic depth to not feel the injection. Due to these difficulties, it 
was eventually decided to use an injectable form of anesthetic; a ketamine/xylazine formulation to allow 
for adequate anesthetic depth and one that did not impede the mode of injection. Once the proper 
anesthetic doses were ascertained, determination of the best injection method was resumed.  
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Another approach used was from a direct anterior approach. The medial border was essentially 
the maxillary buccal bone region. Care was taken to inject as medial as possible so as to not bypass the 
TMJ capsule from a lateral aspect. The superior limit was directly inferior to the zygomatic arch. The last 
variable that is allotted for was the depth of needle injection. Through various attempts it was determined 
that encountering bone and then depositing the dye presented the most consistent results. The portion of 
bone that was encountered could either be the posterior wall of the glenoid fossa; or the direct frontal 
surface of the condylar head.  At either of these injection points the deposition of the dye would logically 
allow for the dye to seep into the compartment and stain the condylar head. This presented about a 70-
80% success rate of injection through repeated trials and it was determined to be the most reliable method 
of injection. As pointed out later in Chapter 6, Future Directions, independent studies can be undertaken 
to determine truly the most effective means of injection. Additionally, the only current method of 
confirming injection other than upon final analysis includes premature euthanization and gross dissection 
to confirm uptake of the dye at the condylar head. Using fluorescent tracers or x-ray methods during 
injection can lend to greater confidence for injection other than waiting for the end of the experiment to 
confirm injection success. 
5.2 Rationale for Specific Mouse Line 
 The use of this mouse line for this study allows for setting the foundation of future determinations 
of the relationship between PLR, cartilage breakdown and OA. Rather than using a global MMP13 
knockout, this specific line has suppression of MMP13 only at the osteocyte level. This is to ensure that 
conclusions drawn regarding the cartilage degradation of the TMJ can be attributed specifically to that of 
the MMP13 knockout in osteocytes. Furthermore, the destruction in the cartilage with a loss of MMP13 
in osteocytes demonstrates the relationship between bone and its overlying cartilage. In a concurrent 
study run within the lab, osteocyte-specific MMP13 ablation increased trabecular bone mass and 
disrupted canalicular and collagen organization. Systemic ablation caused decreased post yield deflection 
and decreased fracture toughness, while osteocyte specific knockout mice demonstrated changes to 
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cortical bone stiffness and ultimate strength only.39 Finally, the value in investigating this mouse line was 
because it allows for a gene knockout whose effects mimic the ingestion or administration of exogenous 
steroids that are sometimes used for suppression of inflammation in OA therapy.  
5.3 The Modified Mankin Scoring 
Severity of OA was assessed using a common scoring tool - Mankin scoring. The general scoring 
protocol was modified for the purposes of this study in only the ‘Chondrocyte Periphery Staining’ 
category.37 The original paper describes an increase in peripheral intensity staining for OA; whereas all 
samples in this study demonstrated a normal to decreased staining intensity. Normal staining intensity 
was given a score of ‘0,’ slightly decreased was ‘1,’ and intensely decreased was ‘2.’ The independent 
graders were calibrated and reviewed various features of OA in order to achieve a consistent assessment 
of the photomicrographs. Grades that presented with a different of more than two points were re-graded 
until they were within two points. These scores were averaged and the sum total of the modified Mankin 
score was used for statistics. Normalcy of the data was assumed, as well as ensuring the test was for 
independent, two tailed groups. With a larger sample size, the more ideal statistical measure would have 
been the Mann-Whitney test because it allows for non-normal data.  
Cartilage erosion scoring and cartilage periphery staining was determined by examining the 
border outline of the condylar head. Periphery staining was assessed by ascertaining if the border of the 
condyle demonstrated a normal amount of safranin dye as compared to the rest of the cartilage layer; or if 
it presented as slightly or intensely decreased.  
Spatial arrangement of the chondrocytes was scored based of the organization and quality of the 
chondrocytes. For example, the left panel 1 of Figures 4.3 to 4.6 for 0.10 mg MIA WT demonstrates an 
absolute loss of cellularity and disorganization of the cells. In comparison, panel 2 of Figure 16 for the 
WT row shows a generally normal pattern of chondrocyte proliferation with stacked cells. Background 
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staining intensity was assessed by viewing the uptake of safranin along the cartilage layer which varied 
from a pale pink to an intense, normal red. 
5.4. Histologic Findings of the Effects of MIA on the TMJ  
Figures 4.3 to 4.7 demonstrate that as a whole, the MIA 0.10 mg dose mice resulted in the 
greatest severity of OA features. While the current small sample prevents the derivation of valid statistics, 
with additional samples greater weight can be added to these initial findings. Furthermore, the obvious 
loss of cells at the condylar level demonstrate the effectiveness of MIA as an injury model for OA. The 
only trend difference observed in Figure 4.7 is the scores for cartilage erosion scoring. Further sub-
analysis can be done for this category once a sufficient n is achieved. Our results are consistent with other 
studies using MIA as a method for OA induction – even with different animals and different locations. 
For example, punctuate allodynia and weight bearing deficits in rats injected with MIA has been 
demonstrated for up to 10 weeks and was able to be reversed with pain medications.18 Similarly, our 
foundational paper demonstrated that OA-inducing effects of MIA on rat TMJs can be observed within 
just a few days.25 Knee OA has also been induced with MIA in rabbits – with characteristic lesions 
presenting such as thickening and fibrillation. MIA has been used previously as a chemical method to 
induce OA and serves great value as a models for future studies.  
5.5 OA Phenotype in WT and MMP13OCY-/- Mice 
Modified Mankin scoring for the WT and MMP13OCY-/-  in Figure 4.2 demonstrates that the mean scores 
from graders were higher in the WT animals than in MMP13OCY-/- mice. While this is an unexpected 
finding, the differences were not statistically between the two groups. It is plausible that the sample size 
was underpowered and that additional samples with a more consistent protocol could allow for further 
confirmation of this conclusion. A two sample paired t test was utilized to compare individual categories 
as well as the total Mankin score. The t values obtained for cartilage erosion, chondrocyte periphery 
staining, spatial arrangement of chondrocytes, and background staining intensity was 0.059, 0.009, 0.101, 
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and 0.005, respectively (P<0.05, df = 4, tcrit = 2.7). For the total Mankin score tcrit = 2.4 with the t = 0.030. 
In all cases the null was unable to be rejected. The largest culprit in this inability is likely the small 
sample size that does not allow for a smaller tcrit value. If with further samples statistically significant 
greater OA scores are found in WT than MMP13 null mice, this would warrant further investigation as to 
possible mechanisms of spontaneous OA in WT mice and the protective effect of the absence of MMP13 
in osteocytes in mitigating this OA. Possible suggestions include that the absence of the MMP13 in 
osteocytes could lead to upregulation of other MMPs to ensure homeostasis of the condylar tissues.  
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CHAPTER 6: FUTURE DIRECTIONS 
The proposed studies will serve as a foundation for long term investigations that include determining the 
basis by which defects in osteocyte matrix remodeling affect the function of the fibrocartilage-bone 
complex. To go to the beginning of the study, a new study can be stemmed simply from the injection 
protocol. Various methods were analyzed for this study and the most predictable method of injection was 
chosen. However, a variety of methods and techniques have been presented in the literature for larger 
animals. In this study, using a smaller animal for the purposes of using the specific genetic line of mice 
presented a new challenge in exploring the best method of injection as well as induction of anesthesia. 
Exploring these avenues in studies devoted solely to each individual task would heighten the confidence 
in the conclusions drawn from each respective study. This study explored a single gender within a single 
time point between WT and MMP13OCY-/-. This study sets up the basis for future studies to include both 
sexes, in addition to multiple time points. Furthermore, addition of more samples would allow for greater 
ability to distinguish between inherent variability of such studies and actual significant differences 
between the two animal groups. Although histologic observations showed substantial differences between 
the control and the different MIA dosage groups, increasing the sample size for this determination would 
add to the robustness of the study.  
Additionally, including other quantitative parameters to measure the differences in chondrocyte 
presence and quality can be performed in the future on this sample collected from this study as well as the 
additional animals that could be included. Another dimension of analysis to include for this study is µCT 
analysis. While current methods of µCT analysis are well demarcated for mice knee OA or OA for larger 
animals, studying mice TMJs present additional challenges due to the very small size of tissues. While 
µCT analysis was attempted for this study, several difficulties were encountered in the process of 
attempting to do the analysis. Firstly, the parameters to obtain a high quality image for analysis were 
difficult to identify. A high quality image of the condyle is necessary in order to demarcate the superficial 
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condylar layer from the trabecular bone. Additionally, the thickness of this layer is variable throughout 
the condyle. While a computer program is able to extrapolate estimates of this layer from a starting, 
midpoint, and final region of interest – the exact thickness is unknown.  Follow up work with a lab 
conversant with µCT analyses of TMJs are currently being pursued.  
In the longer term, we intend to decipher whether the progression and severity of OA in response 
to subchondral bone defects are different between joints with hyaline articular cartilage versus the 
fibrocartilage-lined TMJ. Additional future directions of study include testing the ability of molecular 
interventions that rescue osteocyte function to mitigate the severity of TMJ OA. Thus, the work in this 
study, as well as in future proposals will establish the model system and show proof of concept for the 
role of osteocytes in TMJ disease, providing the foundation needed for future studies intended to identify 
new therapeutic interventions. Finally, the data collected from this study will be critical to seeking NIH 
funding to undertake more thorough mechanistic studies on the interactions between subchondral bone 
and fibrocartilage in contributing to progression of OA and the specificity of this response to the TMJ as 
opposed do appendicular hyaline cartilage joints. 
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CHAPTER 7: CONCLUSIONS 
7.1 Injection and Anesthetic Method 
Through the various attempts from this study, it can be concluded that the most predictable method of 
injection is from an anterior aspect, as medial as possible, directly inferior to the zygomatic process. The 
depth limiting factor is the needle tip encountering bone. 
7.2 WT vs MMP13OCY-/- 
Based on the statistical analysis, we are unable to reject the null hypothesis and conclude that there is no 
difference between the osteoarthritic features of the WT vs MMP13OCY-/- mice at 12 to 16 weeks of age. 
This conclusion can be further affirmed by future studies, further calibration of the injection protocol, and 
increasing the sample size. 
7.3 MIA Dosage 
From the observable OA characteristics in the TMJ at 0.10 mg MIA dose, it can be concluded for future 
studies that this is an effective dose to successfully induce OA. Since there appears to be an effect at 0.05 
mg MIA dose, this lower dose may be useful in providing more dynamic range in the severity of injury 
induced OA to discern the combined effects of genotype and injury on TMJ OA. 
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